Published 12 hours ago • loading... • Updated 12 hours ago
Harbour BioMed Appoints Dr. Sanjay Keswani as Scientific Advisor in Neuroscience
Dr. Keswani brings more than 25 years of neuroscience and drug development experience to support Harbour BioMed’s antibody discovery programs.
On Tuesday, November 17, 2026, global biopharmaceutical company Harbour BioMed appointed Dr. Sanjay Keswani as Scientific Advisor in Neuroscience to advance its antibody therapeutic pipeline.
Dr. Keswani brings over 25 years of experience in neuroscience research and pharmaceutical development, having recently served as Chief Medical Officer of Neurocrine Biosciences leading clinical programs.
At Roche, Keswani led a global organization of approximately 250 professionals and advanced five molecules into Phase 3 clinical development, including therapies for spinal muscular atrophy and diabetic macular edema.
Dr. Jingsong Wang, Founder, Chairman and CEO of Harbour BioMed, said, "We are delighted to welcome Dr. Keswani as our Scientific Advisor in Neuroscience," citing his proven expertise.
"I look forward to contributing my experience in neuroscience and drug development to support the Company," said Dr. Keswani, joining the firm's proprietary HCAb-based antibody technology initiatives.